Standing Committee on the Law of Patents

Standing Committee on the Law of Patents
Name	Standing Committee on the Law of Patents
Abbreviation	SCLP
Formed	1999
Parent organization	World Intellectual Property Organization
Headquarters	Geneva
Membership	193 member states

Contents

Standing Committee on the Law of Patents The Standing Committee on the Law of Patents is an expert intergovernmental body that develops policy, harmonization measures, and technical guidance on patent law and practice within the framework of the World Intellectual Property Organization in Geneva. The committee interacts with national offices such as the United States Patent and Trademark Office, the European Patent Office, and the Japan Patent Office, and with international instruments such as the Patent Cooperation Treaty and the Agreement on Trade-Related Aspects of Intellectual Property Rights. It convenes member delegations, non-governmental organizations like the International Federation of Intellectual Property Attorneys, and observer organizations including the World Health Organization and the Organisation for Economic Co-operation and Development.

History

The committee was established by the World Intellectual Property Organization in 1999 to provide a permanent forum after ad hoc discussions during meetings involving the WIPO General Assembly, the WIPO Coordination Committee, and expert consultations linked to the TRIPS Council and the United Nations Conference on Trade and Development. Early sessions built on comparative studies from national systems such as the Patent Law Treaty negotiations, with inputs referencing jurisprudence from the Supreme Court of the United States, the Court of Justice of the European Union, and patent law reforms in jurisdictions like China, India, and Brazil. Over successive sessions the committee addressed substantive topics appearing in instruments like the European Patent Convention and institutional practices at offices including the Korean Intellectual Property Office and the Russian Federal Service for Intellectual Property.

Under the aegis of the World Intellectual Property Organization, the committee’s mandate encompasses comparative analysis of patentability criteria, patent exceptions, enforcement measures, and procedural harmonization, often drawing on models exemplified by the United States Patent Act, the European Patent Convention, and the German Patent Act. It prepares study papers, draft provisions, and guidance documents that inform negotiations in bodies such as the TRIPS Council and influence treaty projects like the Patent Law Treaty. The committee liaises with technical agencies such as the World Health Organization on public health-related flexibilities and with trade institutions such as the World Trade Organization on TRIPS interpretation, while consulting NGOs including Médecins Sans Frontières, rights holders like the International Federation of Pharmaceutical Manufacturers & Associations, and industry associations like the International Chamber of Commerce.

Membership comprises delegations from WIPO Member States, including representatives from ministries and national offices such as the United States Patent and Trademark Office, the European Patent Office, and the Japan Patent Office. Observers include intergovernmental organizations like the World Health Organization, the Organisation for Economic Co-operation and Development, and the United Nations Development Programme, as well as non-governmental organizations such as the International Federation of Intellectual Property Attorneys and the International Association for the Protection of Intellectual Property. The committee elects a chair from among member delegations and organizes working groups reflecting priorities linked to instruments like the Patent Cooperation Treaty and the Patent Law Treaty, with logistical support from the WIPO Secretariat.

The committee meets regularly in Geneva at WIPO headquarters, scheduling sessions that produce working documents, study reports, and draft recommendations cited by national legislatures and courts such as the Supreme Court of the United States and the Court of Justice of the European Union. Reports draw on comparative surveys of practice from offices including the European Patent Office, the Japan Patent Office, the Korean Intellectual Property Office, and the China National Intellectual Property Administration. Sessions have been characterized by multilateral negotiations involving delegations from United States, European Union, India, Brazil, and China, and by participation of civil society organizations such as Médecins Sans Frontières and industry groups like the International Federation of Pharmaceutical Manufacturers & Associations.

The committee’s work program covers patentability criteria with reference to cases from the Supreme Court of the United States (for example in biotechnology and software), exceptions and limitations including research exemptions debated alongside inputs from the World Health Organization and Médecins Sans Frontières, patent quality and opposition systems modeled on the European Patent Convention and national regimes, and patent enforcement topics intersecting with the Agreement on Trade-Related Aspects of Intellectual Property Rights jurisprudence. Other agenda items include interactions with the Patent Cooperation Treaty system, standards for genetic resources and traditional knowledge informed by the Convention on Biological Diversity and the Nagoya Protocol, and digital sequence listings influenced by standards from the International Organization for Standardization.

The committee has influenced legislative reforms in jurisdictions citing comparative reports produced at WIPO, and has informed judicial reasoning in forums such as the Court of Justice of the European Union and national high courts. Advocates including industry organizations like the International Chamber of Commerce and the International Federation of Pharmaceutical Manufacturers & Associations credit the committee with improving patent quality and international predictability, while critics such as Médecins Sans Frontières, public interest law groups, and delegations from India and Brazil argue that some proposals risk prioritizing rights holders over access to medicines and technology transfer obligations under the TRIPS Agreement and the United Nations Framework Convention on Climate Change-related technology discussions. Debates continue about transparency, stakeholder participation, and the balance between harmonization exemplified by the European Patent Convention and national regulatory autonomy in countries like China and India.